Last Posted: Nov 15, 2018
- A Recurrent BRCA2 Mutation Explains the Majority of Hereditary Breast and Ovarian Cancer Syndrome Cases in Puerto Rico.
Diaz-Zabala Hector J et al. Cancers 2018 Nov 10(11) - Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
Ditchi Yoan et al. The breast journal 2018 Nov - Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer.
Ladd Mary Kathleen et al. Translational behavioral medicine 2018 Nov - Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer.
Kiely B E et al. Familial cancer 2011 Sep 10(3) 505-14 - Assessing the Risk of Occult Cancer and 30-day Morbidity in Women Undergoing Risk-reducing Surgery: A Prospective Experience.
Bogani Giorgio et al. Journal of minimally invasive gynecology 24(5) 837-842 - FDA clears the first consumer genetic test for how well your medications may work — with caveats
R Robbins, StatNews, October 31, 2018 - Take it from a genetic counselor: 23andMe's health reports are dangerously incomplete
SC Hopkins, October 26, LA Times, October 2018 - Association of BRCA1 185 del AG with early age onset of breast cancer patients in selected cohort from Pakistani population.
Durr-E-Samin et al. Pakistan journal of medical sciences 34(5) 1158-1163 - Cancer-related distress in unselected women with newly diagnosed breast or ovarian cancer undergoing BRCA1/2 testing without pretest genetic counseling.
Høberg-Vetti Hildegunn et al. Acta oncologica (Stockholm, Sweden) 2018 Oct 1-7 - Familial risks of second primary cancers and mortality in ovarian cancer patients.
Zheng Guoqiao et al. Clinical epidemiology 2018 101457-1466
.png)
No hay comentarios:
Publicar un comentario